Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TSN084
i
Other names:
TSN084
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Tyligand
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TAS-115 (0)
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TAS-115 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.